In comparison, CREB3L1 expression levels were abnormally downregulated in tumor samples in 7 cancer types, including bladder urothelial carcinoma (BLCA), colon adenocarcinoma (COAD), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), lung squamous cell carcinoma (LUSC), pheochromocytoma and paraganglioma (PCPG) and rectum adenocarcinoma (READ). Here, CREB3L1 is linked to bladder transitional cell carcinoma.